SCHEMBL17301042

SCHEMBL17301042

O=C(Nc1ncnc2c1ncn2[C@@H]1O[C@H](CO)C(O)[C@@H]1O)c1ccccc1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.72
SLC29A1 Q99808 2/20 0.72
TSHR P16473 2/20 0.72
NFKB1 P19838 2/20 0.72
THPO P40225 2/20 0.72
ALDH1A1 P00352 1/20 0.72
GLA P06280 1/20 0.72
PMP22 Q01453 1/20 0.72
SMN1; SMN2 Q16637 1/20 0.72
NPC1 O15118 1/20 0.72
NPY1R P25929 1/20 0.72
HTT P42858 1/20 0.72
NPY2R P49146 1/20 0.72
RAB9A P51151 1/20 0.72
RXFP1 Q9HBX9 1/20 0.72
CYP1A2 P05177 1/20 0.72
MAPK1 P28482 1/20 0.72
CYP2C19 P33261 1/20 0.72
ADORA3 P0DMS8 4/20 0.69
TP53 P04637 1/20 0.69

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29617913 1.00 LMNA (0.72) LMNASLC29A1TSHRNFKB1THPO
SCHEMBL27986516 1.00 LMNA (0.72) LMNASLC29A1TSHRNFKB1THPO
SCHEMBL17889837 1.00 LMNA (0.72) LMNASLC29A1TSHRNFKB1THPO
SCHEMBL313413 1.00 LMNA (0.72) LMNASLC29A1TSHRNFKB1THPO
SCHEMBL6909853 1.00 LMNA (0.72) LMNASLC29A1TSHRNFKB1THPO
SCHEMBL9945526 1.00 LMNA (0.72) LMNASLC29A1TSHRNFKB1THPO
SCHEMBL19485512 1.00 LMNA (0.72) LMNASLC29A1TSHRNFKB1THPO
SCHEMBL233209 1.00 LMNA (0.72) LMNASLC29A1TSHRNFKB1THPO
SCHEMBL21953578 1.00 LMNA (0.72) LMNASLC29A1TSHRNFKB1THPO
SCHEMBL233208 1.00 LMNA (0.72) LMNASLC29A1TSHRNFKB1THPO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11840551-B2 Compositions and methods of modulating the immune response by activating alpha protein kinase 1 SHANGHAI YAO YUAN BIOTECHNOLOGY CO., LTD. (CN) 2023-12-12 US disclosed
US-20170296655-A1 Pharmaceutical targeting of a mammalian cyclic di-nucleotide signaling pathway BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2017-10-19 US disclosed
US-20170037076-A1 DITHIOLANE FUNCTIONALIZED NUCLEOSIDE AMIDITES AND SUPPORTS FOR STRONGER IMMOBILIZATION OF BIO-MOLECULES ON SOLID SURFACES CHEMGENES CORPORATION 2017-02-09 US disclosed
US-20150343056-A1 PHARMACEUTICAL TARGETING OF A MAMMALIAN CYCLIC DI-NUCLEOTIDE SIGNALING PATHWAY BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2015-12-03 US disclosed
US-20150343056-A1 PHARMACEUTICAL TARGETING OF A MAMMALIAN CYCLIC DI-NUCLEOTIDE SIGNALING PATHWAY BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2015-12-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11840551-B2 Compositions and methods of modulating the immune response by activating alpha protein kinase 1 PHKA1, PHKA2, PRKCA LMNA 1674/4885SLC29A1 4529/4885TSHR 2816/4885
US-20170296655-A1 Pharmaceutical targeting of a mammalian cyclic di-nucleotide signaling pathway CGAS, PDE11A, MAVS LMNA 3564/4885SLC29A1 1453/4885TSHR 2067/4885
US-20150343056-A1 PHARMACEUTICAL TARGETING OF A MAMMALIAN CYCLIC DI-NUCLEOTIDE SIGNALING PATHWAY CGAS, GMPS, STING1 LMNA 3897/4885SLC29A1 1454/4885TSHR 1774/4885
US-20170037076-A1 DITHIOLANE FUNCTIONALIZED NUCLEOSIDE AMIDITES AND SUPPORTS FOR STRONGER IMMOBILIZATION OF BIO-MOLECULES ON SOLID SURFACES RNGTT, DIMT1, ADAR LMNA 3088/4885SLC29A1 182/4885TSHR 319/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.